Navigation Links
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Date:12/11/2008

09.

-- IMC-A12 is a fully-human monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R). Phase II testing is underway in breast, prostate, pancreatic, colorectal, liver and head and neck cancers, as well as sarcoma, with Phase III trials planned in 2009. IMC-A12 has the potential to work with a variety of other targeted agents.

-- IMC-11F8 is a potent, fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is currently in Phase II studies for metastatic colorectal cancer with one or more Phase III trials planned in 2009.

In summarizing Lilly's research and development potential, Dr. Paul concluded, "Despite the challenges we face, the opportunities are also growing - the science has never been richer and there is no lack of unmet medical needs that we can address through our R&D efforts."

Commercial Performance - Top 10 in Worldwide Sales, Fastest Growing U.S. Pharma

Derica Rice, Lilly's chief financial officer, provided an update on the company's commercial performance, focusing on the five key medicines that are driving top-line growth (Cymbalta(R), Byetta(R), Humalog(R), Cialis(R), and Alimta(R)), as well as the company's largest-selling product, Zyprexa, and Elanco, the company's animal health division.

"Lilly is completing another year of solid operating performance," said Rice. "The strong results we've seen year-to-date reflect an ongoing focus on execution across all geographies and across our product portfolio. This positions us for success in 2009 and will enable us to effectively deal with the patent expirations we will face in the next decade."

Through the first nine months of 2008, the company's sales have grown 12 percent on a pro forma basis, with fully half of that growth, or 6 percent, resulting from volume gains in most major geographic areas. According to rankings
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... functional food, and dietary supplement products with strong scientific roots ... ... North Brunswick, NJ and Blauvelt, NY (PRWEB) December ... crossroads of foods and pharmaceuticals, and RFI Ingredients, a manufacturer ... of a Memorandum of Understanding (MOU) covering a range of ...
(Date:12/16/2009)... scientists at the University of East Anglia (UEA) could ... or agricultural waste to generate clean electricity. , Published ... the National Academy of Sciences (PNAS), the researchers ... which some bacteria survive by ,breathing rocks,. , The ... of new microbe-based technologies such as fuel cells, or ...
(Date:12/16/2009)... months after the Nanyang Technological University (NTU) signed ... National Center for Scientific Research (CNRS) and the ... joint research laboratory, the three parties are meeting ... Alliance (CINTRA) Laboratory at NTU. , Located ... aims to harness the latest in science and ...
(Date:12/16/2009)... in the Nation ,, PHILADELPHIA, Dec. 16 ... has been granted Magnet(R) recognition by the American ... is one of the highest levels of recognition ... places Hahnemann among the five percent of hospitals ... distinction. ,, At 9:00 am on Monday, Hahnemann ...
Breaking Biology Technology:WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 2WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 3'Rock-breathing' bacteria could generate electricity and clean up oil spills 2New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3
... MOUNTAIN VIEW, Calif., Oct. 14 Clontech Laboratories,Inc., ... the three,winners of the 2008 Nobel Prize in ... Tsien, for the discovery and development of the ... related fluorescent proteins.,The application of fluorescent proteins as ...
... divisions that include in vitro diagnostics, cancer therapeutics and ... ... Oct. 14 ( http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), ... US, today announced it has restructured,its business into three distinct divisions ...
... Oct. 14 Nyer Medical Group,Inc. (Nasdaq: NYER ) ... for the fiscal year ended June 30, 2008 increased $6.6,million ... for the,previous fiscal year. Net loss for the fiscal year ... compared to a net income of $86,446 or $.02,per share ...
Other Biology Technology:Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry 2AMDL, Inc. Announces Strategic Realignment 2AMDL, Inc. Announces Strategic Realignment 3Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008 2Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008 3
(Date:12/16/2009)... financial and technical assistance to developing countries around the ... be connected to space technology, but large development projects ... , Global climate change is also an increasingly important ... poorest countries and communities, which will suffer the earliest ... a growing demand for information about the state of ...
(Date:12/16/2009)... 15, 2009 Signal Hill, CA Tom Bowman, ... and president of Bowman Global Change, has developed a ... fourth Intergovernmental Panel on Climate Change (IPCC) report for ... the authentic scientific information they need to make informed ... created the new format as a means to clearly ...
(Date:12/16/2009)... Calif. and PALM HARBOR, Fla., Dec. 2 ... Bulletin Board: CICI), a leading supplier of ... in the financial industry* and the recognized ... Systems Inc. ("Docubase"), a leading International Electronic ... that they have entered an agreement to ...
Breaking Biology News(10 mins):ESA and World Bank move toward closer collaboration 2ESA and World Bank move toward closer collaboration 3ESA and World Bank move toward closer collaboration 4Bowman creates graphic translation of climate change data 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 1Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 2Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 3Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 4Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 51435 1Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 51435 2Victory Pharma Inc Announces FDA Accepts MGX006 NDA for Review 51430 1Victory Pharma Inc Announces FDA Accepts MGX006 NDA for Review 51430 2
... time when peeking at another student,s work during class ... when only televisions had clickers, not classrooms. , Starting ... biology lab sections at Worcester Polytechnic Institute (WPI) have ... that promises to improve student-achievement and enhance teaching during ...
... the waning months of the First World War, a ... subtype H1N1), swept the United States, Europe and Asia ... ensuing pandemic claimed up to 100 million victims, most ... rapidly progressing pneumonia. Many died within days of the ...
... the elevated carbon dioxide (CO 2 ) levels predicted for ... atmospheric conditions, researchers report, a finding that will help fine-tune ... CO 2 levels rise. , The study, from researchers ... Agriculture, appears this week in the Proceedings of the ...
Other Biology News:At WPI, some students are learning it's OK to peek 2At WPI, some students are learning it's OK to peek 3At WPI, some students are learning it's OK to peek 4Shades of 1918? New study compares avian flu with a notorious killer from the past 2Shades of 1918? New study compares avian flu with a notorious killer from the past 3Shades of 1918? New study compares avian flu with a notorious killer from the past 4Shades of 1918? New study compares avian flu with a notorious killer from the past 5High CO2 boosts plant respiration, potentially affecting climate and crops 2
...
Use as the souce of CETP enzyme for screening CETP inhibitors. Use in conjunction with the CETP activity assay kit (K601-100)....
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
Biology Products: